Duchenne muscular dystrophy diagnosis using fibroblast-derived myotube cells

Yuki Okada^{1

2}, Michinori Funato¹, Shin'ichi Takeda³, Hideo Kaneko^{1

2}

Affiliations

¹ Department of Pediatrics, National Hospital Organization Nagara Medical Center, Gifu, Japan.
² Department of Pediatric Medical Care, Gifu Prefectural General Medical Center, Gifu, Japan.
³ Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Japan.

Yuki Okada et al. Pediatr Int. 2022 Jan.

. 2022 Jan;64(1):e15151.

doi: 10.1111/ped.15151.

Yuki Okada^{1

2}, Michinori Funato¹, Shin'ichi Takeda³, Hideo Kaneko^{1

2}

¹ Department of Pediatrics, National Hospital Organization Nagara Medical Center, Gifu, Japan.
² Department of Pediatric Medical Care, Gifu Prefectural General Medical Center, Gifu, Japan.
³ Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Japan.

No abstract available

Keywords: Becker muscular dystrophy; Duchenne muscular dystrophy; dystrophin protein; fibroblast cells; nonsense mutation.

References

1. Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat. Rev. Dis. Primers 2021; 7 (1): 13.
1. Kameyama T, Ohuchi K, Funato M et al. Efficacy of prednisolone in generated myotubes derived from fibroblasts of Duchenne muscular dystrophy patients. Front. Pharmacol. 2018; 3(9): 1402.
1. Saito T, Nakamura A, Aoki Y et al. Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One 2010; 5: e12239.
1. Tyers L, Davids LM, Wilmshurst JM, Esterhuizen AI. Skin cells for use in an alternate diagnostic method for Duchenne muscular dystrophy. Neuromuscul. Disord. 2018; 28: 553-63.